Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course.

Autor: Muri J; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Cecchinato V; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Cavalli A; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. andrea.cavalli@irb.usi.ch.; Swiss Institute of Bioinformatics, Lausanne, Switzerland. andrea.cavalli@irb.usi.ch., Shanbhag AA; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Matkovic M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Biggiogero M; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland., Maida PA; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland., Moritz J; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Toscano C; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Ghovehoud E; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Furlan R; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Internal Medicine, IRCCS Humanitas Research Hospital, Milan, Italy., Barbic F; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Internal Medicine, IRCCS Humanitas Research Hospital, Milan, Italy., Voza A; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Emergency, IRCCS Humanitas Research Hospital, Milan, Italy., De Nadai G; Emergency Medicine Residency School, Department of Biomedical Sciences, Humanitas University, Milan, Italy., Cervia C; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Zurbuchen Y; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Taeschler P; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Murray LA; Lyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA., Danelon-Sargenti G; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Moro S; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Gong T; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Piffaretti P; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Bianchini F; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Crivelli V; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Podešvová L; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Pedotti M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Jarrossay D; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Sgrignani J; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Thelen S; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Uhr M; Synlab Suisse, Bioggio, Switzerland., Bernasconi E; Regional Hospital Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Università della Svizzera italiana, Lugano, Switzerland., Rauch A; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Manzo A; Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy., Ciurea A; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Rocchi MBL; Department of Biomolecular Sciences, Biostatistics Unit, University of Urbino, Urbino, Italy., Varani L; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Moser B; Division of Infection & Immunity, Cardiff University School of Medicine, Cardiff, UK., Bottazzi B; IRCCS Humanitas Research Hospital, Milan, Italy., Thelen M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland., Fallon BA; Lyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.; Lyme Research Program at the New York State Psychiatric Institute, New York, NY, USA., Boyman O; Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Faculty of Medicine and Faculty of Science, University of Zurich, Zurich, Switzerland., Mantovani A; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; IRCCS Humanitas Research Hospital, Milan, Italy.; The William Harvey Research Institute, Queen Mary University of London, London, UK., Garzoni C; Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland., Franzetti-Pellanda A; Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland., Uguccioni M; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. mariagrazia.uguccioni@irb.usi.ch.; Department of Biomedical Sciences, Humanitas University, Milan, Italy. mariagrazia.uguccioni@irb.usi.ch., Robbiani DF; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. drobbiani@irb.usi.ch.
Jazyk: angličtina
Zdroj: Nature immunology [Nat Immunol] 2023 Apr; Vol. 24 (4), pp. 604-611. Date of Electronic Publication: 2023 Mar 06.
DOI: 10.1038/s41590-023-01445-w
Abstrakt: Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: